Small venture healthcare assets in the Asia-Pacific region are evolving into growth equity opportunities for investors. As a result, the number of buyouts rose sharply in 2020 to 156 deals, compared with 68 in 2019. Disclosed values shot up to a new high of $16.9 billion, compared with $11 billion the prior year. Biopharma was the most active sector, and China led the way with just over 60% of deals in the region. Investors increasingly focused on domestic innovation in biopharma and medtech, especially in China, where the government has supported development of local companies through various incentives. The industry also benefits from an aging population, increasingly affordable care, a shift to universal healthcare coverage in markets such as India, and the rapid adoption of digital health solutions.
Investors see underserved demand and favorable shifts in healthcare policies.